Pharmacokinetic Bioequivalence Crossover Study of Branded Generic and Innovator Formulations of the Cholesterol Lowering Agent Ezetimibe

被引：7

作者：

Palmer, Jonathan L. ^{[1
]}

Kunhihitlu, Anil ^{[2
]}

Costantini, Andrea ^{[3
]}

Esquivel, Florencia ^{[3
]}

Roush, John ^{[4
]}

Edwards, Karina ^{[5
]}

Hill, Thomas W. K. ^{[6
]}

机构：

[1] GlaxoSmithKline, Uxbridge UB11 1BT, Middx, England

[2] Clinigene Int Ltd, Bangalore, Karnataka, India

[3] Labs Phoenix SAICF, Malvinas Argentinas, Provincia Bueno, Argentina

[4] GlaxoSmithKline, Res Triangle Pk, NC USA

[5] GlaxoSmithKline, Harlow, Essex, England

[6] Biopharma Consulting Ltd, Colwyn Bay, Wales

来源：

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2014年 / 3卷 / 03期

关键词：

bioequivalence; ezetimibe; branded generic; innovator; NPC1L1;

D O I：

10.1002/cpdd.80

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：242 / 248

页数：7

共 12 条

[1]

[Anonymous], 2010, GUID INV BIOEQ

[2] The discovery of ezetimibe: A view from outside the receptor [J].

Clader, JW .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (01) :1-9

[3] Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter [J].

Davis, Harry R., Jr. ;

Altmann, Scott W. .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2009, 1791 (07) :679-683

[4] Complex Pharmacokinetic Behavior of Ezetimibe Depends on Abcc2, Abcc3, and Abcg2 [J].

de Waart, Dirk R. ;

Vlaming, Maria L. H. ;

Kunne, Cindy ;

Schinkel, Alfred H. ;

Elferink, Ronald P. J. Oude .

DRUG METABOLISM AND DISPOSITION, 2009, 37 (08) :1698-1702

[5] Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers [J].

Del Tacca, Mario ;

Pasqualetti, Giuseppe ;

Di Paolo, Antonello ;

Virdis, Agostino ;

Massimetti, Gabriele ;

Gori, Giovanni ;

Versari, Daniele ;

Taddei, Stefano ;

Blandizzi, Corrado .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) :34-42

[6] A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe [J].

Ezzet, F ;

Krishna, G ;

Wexler, DB ;

Statkevich, P ;

Kosoglou, T ;

Batra, VK .

CLINICAL THERAPEUTICS, 2001, 23 (06) :871-885

[7] The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1) [J].

Garcia-Calvo, M ;

Lisnock, JM ;

Bull, HG ;

Hawes, BE ;

Burnett, DA ;

Braun, MP ;

Crona, JH ;

Davis, HR ;

Dean, DC ;

Detmers, PA ;

Graziano, MP ;

Hughes, M ;

MacIntyre, DE ;

Ogawa, A ;

O'Neill, KA ;

Iyer, SPN ;

Shevell, DE ;

Smith, MM ;

Tang, YS ;

Makarewicz, AM ;

Ujjainwalla, F ;

Altmann, SW ;

Chapman, KT ;

Thornberry, NA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (23) :8132-8137

[8]

*HHS FDA, 2003, GUID IND BIOAV BIOEQ

[9] Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects [J].

Kosoglou, Teddy ;

Zhu, Yali ;

Statkevich, Paul ;

Triantafyllou, Ilias ;

Taggart, William ;

Xuan, Fengjuan ;

Kim, Kenneth T. ;

Cutler, David L. .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (05) :483-492

[10] Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects [J].

Patrick, JE ;

Kosoglou, T ;

Stauber, KL ;

Alton, KB ;

Maxwell, SE ;

Zhu, YL ;

Statkevich, P ;

Iannucci, R ;

Chowdhury, S ;

Affrime, M ;

Cayen, MN .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :430-437

← 1 2 →